Bio-Techne Corporation

Bio-Techne Corporation

TECHNYSE / NASDAQHealthcareMid cap

$72.67-$0.03 (0.0%)

Last close · Data as of Nov 20, 2026

Market cap
$8.3B
P/E
113.5x
EV / EBITDA
39.7x
Revenue
$1.2B
Net margin
6.0%
ROCE
4.7%

+23.7% over the last year

Bio-Techne Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.1%
3M
+0.5%
6M
+55.6%
1Y
+23.7%
5Y
-42.0%

52-week range

Day change -$0.03 (0.0%) from $73 to $73 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TECH, bought on each weekday since 2021.

News & filings

What Bio-Techne filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernNet profit fell 35.4% a year over three years.

Strengths (1)

  • Free cash flow was 3.50 times net profit in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.

Read moreShow less

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Sector
Healthcare
Shares outstanding
155.0M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$8.3B
P/E
113.5x
P/B
4.3x
EV / EBITDA
39.7x
EV / Sales
7.1x
P/S
6.8x
52-week high
$72.84
52-week low
$43.30

Profitability

Operating margin
19.9%
Net margin
6.0%
EBITDA margin
17.8%
ROE
3.8%
ROCE
4.7%
ROA
2.9%
Asset turnover
0.48

Growth

Revenue
$1.2B
Revenue growth, 1Y
5.2%
Revenue CAGR, 3Y
3.3%
Net profit growth, 1Y
-56.3%
Free cash flow
$256.6M

Solvency

Current ratio
3.46
Debt / Equity
0.23
Debt / Assets
0.17
CFO / Net profit
3.92
Cash / Market cap
1.9%

Where the revenue went

Of every $100 of FY2025 revenue, $6 was left as net income.

Bio-Techne Corporation income statement flow, FY2025
Bio-Techne Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$429.4M
RevenueGross profit$790.3M
Gross profitResearch and development$99.5M
Gross profitSelling, general and administrative$415.1M
Gross profitOther operating expenses$32.9M
Gross profitOperating income$242.8M
Operating incomePretax income$98.5M
Operating incomeInterest and other expense$144.3M
Pretax incomeTax and other$25.1M
Pretax incomeNet income$73.4M

Revenue and net profit

Revenue grew 5.2% in FY2025; net profit is the dashed line.

Bio-Techne Corporation revenue and net profit by fiscal year
Bio-Techne Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.1B$272.1M
FY2023$1.1B$285.3M
FY2024$1.2B$168.1M
FY2025$1.2B$73.4M

Cash flows

FY2025: $287.6M from operations, $256.6M free after investment (dashed).

Bio-Techne Corporation operating and free cash flow by fiscal year
Bio-Techne Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$325.3M$280.4M
FY2023$254.4M$216.1M
FY2024$299.0M$236.1M
FY2025$287.6M$256.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.2B+5.2%1Y
EBITDA
$216.9M-30.7%1Y
Net profit
$73.4M-56.3%1Y
Cash from operations
$287.6M-3.8%1Y
Free cash flow
$256.6M+8.7%1Y
Revenue CAGR, 3Y
3.3%
Net profit CAGR, 3Y
-35.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.2B$216.9M$73.4M$256.6M3.8%+5.2%-56.3%

Monthly returns

Month-by-month returns of TECH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.6B
Liabilities$639.1M
Equity$1.9B
Paid-in capital$911.1M
Retained earnings$1.1B
Minority interest$0.00

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TECH highlighted.

P/E against peers

TECH trades at 113.5x earnings against a peer median of 21.8x (a 420% premium).

  1. Bio-Techne Corporation (this company)113.5x

Not shown (no positive earnings and no EV / Sales): Baxter International Inc., Charles River Laboratories International, Inc., Glaukos Corporation, Protagonist Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Bio-Techne CorporationTECHthis companyP/E ↑ premium$8.3B113.5x4.3x3.8%39.7x
Baxter International Inc.BAX$10.0B-10.4x1.6x-15.6%23.2x
Krystal Biotech, Inc.KRYS$9.1B44.3x7.4x16.8%51.2x
Charles River Laboratories International, Inc.CRL$8.9B—2.8x-4.6%27.5x
Henry Schein, Inc.HSIC$8.7B21.8x2.7x12.3%12.4x
Corcept Therapeutics IncorporatedCORT$8.0B80.7x12.4x15.4%66.1x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
Peer median—21.8x5.7x3.9%22.1x

Year-to-date ROI

TECH since 1 January, against earlier years.

Historical volatility

TECH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Bio-Techne Corporation operating margin by fiscal year
Bio-Techne Corporation operating margin by fiscal year
DateOperating margin
FY202226.8%
FY202325.6%
FY202421.3%
FY202519.9%
LineFY2025
Cost of revenueCost Of Revenue$429.4M
Gross profitGross Profit$790.3M
Operating expensesOperating Expense$547.5M
Research and developmentResearch And Development$99.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$31.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$31.3M
Amortization$31.3M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$31.3M
Total expensesTotal Expenses$976.8M
Pretax incomePretax Income$98.5M

Learn while you research

Academy chapters picked for Bio-Techne Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 113.5, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →